BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BC Extra | Jan 15, 2020
Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

Denali reported data Tuesday from pair of Phase I trials that will inform the company’s selection of a Parkinson’s disease candidate to advance to Phase II. Denali Therapeutics Inc. (NASDAQ:DNLI) gained $5.16 (29%) to $22.74...
BioCentury | Jan 10, 2020
Emerging Company Profile

NorthSea: Engineering fatty acids for NASH

With its structurally engineered fatty acid platform and a candidate that can hit the three primary mechanisms behind NASH, NorthSea thinks it can succeed in the hepatic and cardiometabolic disease space where so many others...
BC Innovations | Nov 21, 2019
Distillery Therapeutics

Drug-loaded lipid nanoparticles targeting tumor-associated myeloid cells for glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Targeting immunosuppressive tumor-associated myeloid cells (TAMCs) with drug-loaded anti-PD-L1 lipid nanoparticles could treat glioma, an indication in which TAMCs contribute up to 50% of the tumor mass. The nanoparticles,...
BC Innovations | Aug 29, 2019
Distillery Therapeutics

SPHK1 in T cells identified as melanoma target

DISEASE CATEGORY: Cancer INDICATION: Melanoma Inhibiting SPHK1, which generates the bioactive phospholipid S1P, in T cell therapies could treat melanoma. High tumor expression of SPHK1 was associated with poor survival in skin cancer patients and...
BC Innovations | Nov 26, 2018
Distillery Therapeutics


INDICATION: Heart transplant rejection Mouse studies suggest APOA/phospholipid-based nanoparticles loaded with rapamycin or a TRAF6 inhibitor could help prevent heart transplant rejection. The nanoparticles consist of APOA and natural phospholipid components of HDL cholesterol isolated...
BC Innovations | Jul 17, 2018
Distillery Therapeutics


INDICATION: Breast cancer, melanoma, lung cancer Mouse studies suggest a phospholipid-conjugated TLR7 agonist could help treat metastatic breast cancer, melanoma and lung cancer. The conjugate consists of a previously identified purine-based TLR7 agonist linked to...
BC Innovations | Apr 6, 2018
Targets & Mechanisms

GI Band-Aid

A trio of Science papers shows a leaky gut can drive systemic inflammation and autoimmunity by allowing bacteria and their products to escape the GI lumen and enter the bloodstream. The results open a variety...
BC Innovations | Jan 9, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection; Escherichia; Pseudomonas; Salmonella Cell culture studies suggest engineered virus-like capsids could be used to treat a range of bacterial infections. The capsids consist of 21- and 23-mer peptide sequences designed to self-assemble...
BC Week In Review | Oct 13, 2017
Company News

Cellectar and Pierre Fabre extend PDC deal

Cellectar Biosciences Inc. (NASDAQ:CLRB) and Pierre Fabre Group (Castres, France) extended a 2015 deal to develop phospholipid drug conjugates (PDC) to treat cancer. The companies said the extension will cover combining Pierre Fabre's cytotoxic payloads...
Items per page:
1 - 10 of 199